Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EpiPen's Swollen Price May Trigger Patient Assistance Program Probes

Executive Summary

Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.

You may also be interested in...



Teva Launches Generic EpiPen At Same Price As Mylan's Generic

Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.

Teva Launches Generic EpiPen At Same Price As Mylan's Generic

Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.

Mylan CEO Heather Bresch On How Mylan Is Different Than Teva

CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel